Abstract
Aurora inhibitors have been extensively studied as potential novel anticancer agents. At least four compounds are now under clinical evaluation. Banyu discloses aminopyridines and -pyrazines acting as selective Aurora-A inhibitors. The claimed compounds demonstrated low nanomolar activity in the biochemical assay and exhibit a 200-fold specificity on Aurora-A versus Aurora-B.